GlassScriptPhysician profile
Krystina E Zeliff
NPI 1588086821
$522.60
in general payments reported to CMS, 2019-2025
16 companies · $516 in 2025
The $516 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6.93 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $516.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $515.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $104.13 | 2025 | Mounjaro, Zepbound, Omvoh |
| Otsuka America Pharmaceutical, INC. | $85.71 | 2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $66.13 | 2025 | Airsupra, Breztri |
| Alkermes, INC. | $50.52 | 2025 | Vivitrol |
| Janssen Biotech, INC. | $35.12 | 2025 | Tremfya |
| Exact Sciences Corporation | $21.00 | 2025 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $19.25 | 2025 | Aptima |
| Abbvie INC. | $18.07 | 2025 | |
| Corcept Therapeutics | $17.61 | 2025 | Korlym |
| Modernatx, INC. | $17.00 | 2025 | Mresvia |
| Madrigal Pharmaceuticals | $16.66 | 2025 | Rezdiffra |
| Amgen INC. | $16.65 | 2025 | Prolia, Evenity |
| Glaxosmithkline, LLC. | $16.30 | 2025 | Shingrix |
| Lundbeck LLC | $15.82 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $15.70 | 2025 | Auvelity |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $6.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krystina Zeliff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.